Document is current
Any future updates will be listed below
-
Authors
Woxholt, Sindre https://orcid.org/0000-0002-8512-9609
Ueland, T
Aukrust, Pål
Anstensrud, Anne Kristine https://orcid.org/0000-0003-1499-2402
Broch, Kaspar
Tøllefsen, Ingvild Maria https://orcid.org/0000-0003-4972-3093
Ryan, Liv
Bendz, Bjørn https://orcid.org/0000-0002-1392-6481
Hopp, Einar
Kløw, Nils-Einar
Seljeflot, Ingebjørg
Halvorsen, Bente
Dahl, Tuva B
Huse, Camilla
Andersen, Geir Øystein
Gullestad, Lars
Wiseth, Rune https://orcid.org/0000-0002-5097-4554
Amundsen, Brage H
Damas, Jan Kristian
Kleveland, Ola
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03004703 at ClinicalTrials.govnct03004703 at ClinicalTrials.govDocuments that mention this clinical trial
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
https://doi.org/10.1136/openhrt-2023-002301
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
https://doi.org/10.1136/openhrt-2019-001108
Documents that mention this clinical trial
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
https://doi.org/10.1136/openhrt-2023-002301
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
https://doi.org/10.1136/openhrt-2019-001108
-
Funding
Funding for this research was provided by:
Roche
Central Norway Regional Health Authority
South-Eastern Norway Regional Health Authority
- License Information
